24 citations
,
June 2016 in “Acta dermato-venereologica” In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.
September 2023 in “Journal of the American Academy of Dermatology” This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.
3 citations
,
August 2020 in “Case Reports in Dermatology” This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
9 citations
,
July 2018 in “European Journal of Dermatology” Brodalumab effectively treated a man's severe hand and foot psoriasis.
This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
October 2021 in “Dermatology reports” The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
February 2010 in “Journal of The American Academy of Dermatology” This study found that nonobese women with idiopathic hirsutism had significantly lower nitrite/nitrate concentrations and higher fibrinogen levels compared to controls, but similar levels to women with PCOS.
5 citations
,
October 2024 in “Reumatismo” This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.
May 2025 in “JEADV Clinical Practice” This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.
7 citations
,
April 2013 in “International Journal of Rheumatic Diseases” This case report highlights a potential association between etanercept, a TNF-α blocker, and the onset of alopecia areata, suggesting complex interactions between anti-TNF-α treatments and hair follicle growth.
January 2026 in “International Journal of Applied Research” This review examines the potential role of homoeopathy in managing autoimmune diseases, focusing on evidence from recent case reports and studies. It discusses clinical outcomes in various conditions and explores possible immunomodulatory mechanisms associated with homoeopathic interventions.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” This review article highlights that obesity is a significant risk factor for several inflammatory skin conditions, such as psoriasis and atopic eczema, contributing to increased overall morbidity among those affected.
3 citations
,
March 2021 in “JAAD case reports” This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.
November 2024 in “Journal of Investigative Dermatology” Polygenic Score can help predict severe psoriasis and psoriatic arthritis.
1 citations
,
September 2023 in “Rheumatology advances in practice” This case report describes a 42-year-old woman with rheumatoid arthritis who developed extensive impetiginized pityriasis amiantacea potentially linked to her anti-TNF-α therapy with golimumab. Discontinuing the drug and other treatments led to significant clinical improvement within a month.
February 2009 in “Journal of The American Academy of Dermatology” Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.
7 citations
,
August 2005 in “British Journal of Dermatology” This study reported improvement of psoriatic onychopachydermoperiostitis symptoms with the use of etanercept.
13 citations
,
February 2017 in “Clinical rheumatology” This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.
May 2026 in “SKIN The Journal of Cutaneous Medicine” This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.
17 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This report describes two young women with severe psoriasis and alopecia universalis, highlighting the possible but unstudied association between alopecia areata and metabolic syndrome.
June 2026 in “Drugs in Context” This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.
October 2018 in “JAMA Dermatology” This Delphi survey study identified six key domains that should be measured in all future psoriasis clinical trials to ensure comprehensive assessment, including skin manifestations and treatment satisfaction.
March 2014 in “Journal of the American Academy of Dermatology” Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.
20 citations
,
June 2019 in “JAAD Case Reports” This article reviews the use of tofacitinib for rheumatoid and psoriatic arthritis and alopecia areata, noting potential serious side effects, but reports no cases of palmoplantar pustulosis from the therapy.
20 citations
,
March 2017 in “Journal of cutaneous pathology” This study describes tumor necrosis factor inhibitor-associated psoriatic alopecia, highlighting the distinctive histologic feature of sebaceous lobule atrophy, which is potentially reversible and helps differentiate it from idiopathic psoriatic alopecia.
12 citations
,
July 2011 in “European Journal of Dermatology” The authors concluded that VSCAPSI, a videodermoscopy-based assessment tool, provides evidence for early diagnosis, differential diagnosis, follow-up, and screening of scalp psoriasis.
January 2026 in “Clinics and Practice” In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.